At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
SLN360 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
In Brief
A Phase 2 clinical trial evaluating SLN360 and Placebo for Cardiovascular Diseases and 2 related conditions. Completed, enrolled 180 participants across 29 sites in 7 countries.
Detailed Summary
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
CountriesAustralia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartDec 2022
Primary CompletionJan 2024
Study CompletionJul 2024
TodayJul 2026
First PostedSep 13, 2022
Enrollment StartDec 13, 2022
Primary CompletionJan 11, 2024
Study CompletionJul 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.8 years ago
Interventions
SLN360drug
SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
Placebodrug
Sodium chloride, solution for injection